Author:
Goguet Emilie,Olsen Cara H.,Meyer William A.,Ansari Sara,Powers John H.,Conner Tonia L.,Coggins Si’Ana A.,Wang Wei,Wang Richard,Illinik Luca,Sanchez Edwards Margaret,Jackson-Thompson Belinda M.,Hollis-Perry Monique,Wang Gregory,Alcorta Yolanda,Wong Mimi A.,Saunders David,Mohammed Roshila,Balogun Bolatito,Kobi Priscilla,Kosh Lakeesha,Bishop-Lilly Kimberly,Cer Regina Z.,Arnold Catherine E.,Voegtly Logan J.,Fitzpatrick Maren,Luquette Andrea E.,Malagon Francisco,Ortega Orlando,Parmelee Edward,Davies Julian,Lindrose Alyssa R.,Haines-Hull Hannah,Moser Matthew S.,Samuels Emily C.,Rekedal Marana S.,Graydon Elizabeth K.,Malloy Allison M. W.,Tribble David R.,Burgess Timothy H.,Campbell Wesley,Robinson Sara,Broder Christopher C.,O’Connell Robert J.,Weiss Carol D.,Pollett Simon,Laing Eric D.,Mitre Edward
Abstract
IntroductionWe sought to determine pre-infection correlates of protection against SARS-CoV-2 post-vaccine inzfections (PVI) acquired during the first Omicron wave in the United States.MethodsSerum and saliva samples from 176 vaccinated adults were collected from October to December of 2021, immediately before the Omicron wave, and assessed for SARS-CoV-2 Spike-specific IgG and IgA binding antibodies (bAb). Sera were also assessed for bAb using commercial assays, and for neutralization activity against several SARS-CoV-2 variants. PVI duration and severity, as well as risk and precautionary behaviors, were assessed by questionnaires.ResultsSerum anti-Spike IgG levels assessed by research assay, neutralization titers against Omicron subvariants, and low home risk scores correlated with protection against PVIs after multivariable regression analysis. Commercial assays did not perform as well as research assay, likely due to their lower dynamic range.DiscussionIn the 32 participants that developed PVI, anti-Spike IgG bAbs correlated with lower disease severity and shorter duration of illness.
Funder
Defense Health Agency
National Institute of Allergy and Infectious Diseases
Armed Forces Health Surveillance Branch
U.S. Food and Drug Administration